Spondyloarthritis & psoriatic arthritis
Sacroiliac radiographic progression over 10 years in axial spondyloarthritis (axSpA): data from the DESIR inception cohort
Authors' conclusion
The yearly likelihood of switching from nr-axSpA to r-axSpA in patients after 10 years of follow-up was low, and even lower when considering TNFi use.
Study context
- Population
- Patients with recent-onset axSpA (<3 years), DESIR cohortintention-to-follow
- Participants
- 659 patients
- Outcome
- Sacroiliac radiographic progression (mNY criteria): % mNY net progressors in completers; yearly likelihood of mNY+
- Follow-up
- 10 years
Methodological detailsinception cohort, central blinded reading by 3 trained readers, generalised estimating equations model, time-varying tumour necrosis factor (TNF) use as confounder
- Inception cohort
- Central blinded reading by 3 trained readers
- Generalised estimating equations model
- Time-varying TNF use as confounder
Main finding
As reported in the abstract
Net % progression in completers
5.8%
Increase in probability of modified New York (mNY)+ per year (intention-to-follow)
0.87% (95% CI 0.56 to 1.19); 8.7% after 10 years
Increase in probability of mNY+ per year with TNF inhibitors (TNFi) as time-varying covariate
0.45% (95% CI 0.09 to 0.81); 4.5% after 10 years
Observational data: associations, not effects.
Further findings
Baseline BME on MRI of sacroiliac joints (SIJ) and mNY+ over time
| OR (95% CI) | ||
|---|---|---|
| Baseline BME (HLA-B27+) | 6.2 (5.3–7.2) | |
| Baseline BME (HLA-B27-) | 3.1 (2.4–3.9) | |
| 0.10.31310Odds ratio (log scale) |
Other baseline predictors of mNY+ over 10 years
- Male sex, symptom duration >1.5 years, ASDAS ≥2.1 and smoking (only in HLA-B27 positives) also associated with being mNY+
- BME not a mediator of the HLA-B27 effect on mNY+ at 10 years
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →